 |
|
|
| |
EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE 3 STUDY
|
| |
| |
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), Taipei, Taiwan, February 16-19, 2012
Graham R. Foster1, Stuart Roberts2, Stanislas Pol3, Pietro Andreone4, Eric J. Lawitz5, Zobair Younossi6, Rolf van Heeswijk7, Sandra De Meyer7, Gaston Picchio8, and Stefan Zeuzem9
Queen Mary University of London, Institute of Cell and Molecular Science, London, United Kingdom. 2. Department of Gastroenterology, Alfred Hospital, Melbourne, VIC, Australia. 3. Assistance Publique-Hopitaux de Paris, Cochin Hospital, Paris, France. 4. Universita di Bologna, Bologna, Italy. 5. Alamo Medical Research, San Antonio, TX, United States. 6. Center for Liver Diseases and Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, United States. 7. Janssen Infectious Diseases BVBA, Beerse, Belgium. 8. Janssen Research & Development, Titusville, NJ, United States. 9. Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.
*Address correspondence to: Professor Graham R Foster, PhD, FRCP
Centre for Digestive Diseases,
Barts and The London School of Medicine and Dentistry,
4 Newark Street,
London E1 2AT, United Kingdom
g.r.foster@qmul.ac.uk
|
| |
|
|
|
|
|
